BPGbio to Present Phase 2 Study Update on BPM31510 for Glioblastoma at ASCO 2026
BPGbio, a clinical-stage biopharmaceutical company, is set to present new clinical progress from its ongoing Phase 2 study of BPM31510 at the ASCO Annual Meeting in 2026. BPM31510 is a first-in-class therapeutic targeting tumor metabolism, specifically designed to reprogram the mitochondrial microenvironment in Warburg-avid tumors. The study focuses on patients with newly diagnosed glioblastoma multiforme (GBM) who have not received prior therapy. The investigational therapy combines a lipid nanodispersion formulation of oxidized Coenzyme Q10 (CoQ10) with vitamin K1, alongside standard-of-care radiation therapy and temozolomide. The aim is to modulate mitochondrial function, restore oxidative balance, and induce tumor-selective redox stress, potentially increasing the vulnerability of tumor cells in aggressive cancers like glioblastoma. 
